Thrombotic microangiopathy associated with interferon beta

New England Journal of Medicine

Volumn 370, Issue 13, 2014, Pages 1270-1271

  Hunt, David ^a   Kavanagh, David ^b   Drummond, Iain ^a   Weller, Belinda ^a   Bellamy, Chris ^a   Overell, James ^c   Evans, Stephen ^d   Jackson, Andrew ^a   Chandran, Siddharthan ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; LETTER; MALIGNANT HYPERTENSION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED KINGDOM;

GREAT BRITAIN; HUMANS; HYPERTENSION, MALIGNANT; INTERFERON-BETA; KIDNEY; MULTIPLE SCLEROSIS; PHARMACOVIGILANCE; RECOMBINANT PROTEINS; SCOTLAND; THROMBOTIC MICROANGIOPATHIES;

EID: 84896996710     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1316118     Document Type: Letter

References (3)

1. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504. [Erratum, Lancet 1999;353:678.]
2. Recombinant interferon-beta: thrombotic microangiopathy. Drug Safety Update. December 2013:S3. (http://www.mhra.gov.uk/Safetyinformation/ DrugSafetyUpdate/CON355481).
3. Giovannoni G, Barbarash O, Casset-Semanaz F, et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 2009;15:219-28.